<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21281">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829827</url>
  </required_header>
  <id_info>
    <org_study_id>EP0078</org_study_id>
    <secondary_id>2016-002107-26</secondary_id>
    <nct_id>NCT02829827</nct_id>
  </id_info>
  <brief_title>A Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)</brief_title>
  <official_title>An Open-Label Adaptive Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Radiprodil in Subjects With Drug-Resistant Infantile Spasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability, the pharmacokinetics
      and the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant
      infantile spasms
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with clinical response on day 14 of treatment with the maintenance dose of radiprodil</measure>
    <time_frame>Day 14, counting from the first day of radiprodil at maintenance dose</time_frame>
    <description>Clinical response is defined as no spasms on Day 14 of treatment with the maintenance dose of radiprodil. This is the primary efficacy variable for Part A.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with electro-clinical response on day 14 of treatment with the maintenance dose of radiprodil</measure>
    <time_frame>Day 14, counting from the first day of radiprodil at maintenance dose</time_frame>
    <description>Electro-clinical response is defined as no spasms and resolution of hypsarrythmia on Day 14 of treatment with the maintenance dose of radiprodil. This is the primary efficacy variable for Part B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with electro-clinical response on day 14 of treatment with the maintenance dose of radiprodil</measure>
    <time_frame>Day 14, counting from the first day of radiprodil at maintenance dose</time_frame>
    <description>Electro-clinical response is defined as no spasms and resolution of hypsarrythmia on Day 14 of treatment with the maintenance dose of radiprodil. This is the secondary efficacy variable for Part A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical response on day 14 of treatment with the maintenance dose of radiprodil</measure>
    <time_frame>Day 14, counting from Day 14 of treatment with the maintenance dose of radiprodil</time_frame>
    <description>Clinical response is defined as no spasms on Day 14 of treatment with the maintenance dose of radiprodil. This is the secondary efficacy variable for Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cessation of spasms</measure>
    <time_frame>During the first 14 days of treatment with radiprodil</time_frame>
    <description>Time to cessation of spasms for clinical responders on Day 14 of treatment with the maintenance dose of radiprodol. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders with clinical relapse</measure>
    <time_frame>12 months, counting from Day 14 of treatment with the maintenance dose of radiprodil</time_frame>
    <description>The percentage of clinical responders on Day 14 of treatment with the maintenance dose of radiprodil with clinical relapse within 12 months. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical relapse from the day of spasm cessation</measure>
    <time_frame>From day of spasms cessation up to 42 months of age</time_frame>
    <description>This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of electro-clinical responders with electro-clinical relapse</measure>
    <time_frame>12 months, counting from Day 14 of treatment with the maintenance dose of radiprodil</time_frame>
    <description>The percentage of electro-clinical responders on Day 14 of treatment with the maintenance dose of radiprodil with electro-clinical relapse within 12 months. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to electro-clinical relapse from the day of spasm cessation</measure>
    <time_frame>From day of spasms cessation up to 42 months of age</time_frame>
    <description>This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with extended clinical response</measure>
    <time_frame>28 days, counting from Day 14 (inclusive) of treatment with the maintenance dose of radiprodil</time_frame>
    <description>Extended clinical response is defined as no spasms for 28 consecutive days from Day 14 of treatment with the maintenance dose of radiprodil. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with extended electro-clinical response</measure>
    <time_frame>28 days, counting from Day 14 (inclusive) of treatment with the maintenance dose of radiprodil</time_frame>
    <description>Extended electro-clinical response is defined as no spasms and resolution of hypsarrythmia for 28 consecutive days from Day 14 of treatment with the maintenance dose of radiprodil. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Infantile Spasms (IS)</condition>
  <arm_group>
    <arm_group_label>Radiprodil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will enter an individualized dose titration schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiprodil</intervention_name>
    <description>Pharmaceutical form: Granules and solvent for oral suspension
Route of administration: Oral use</description>
    <arm_group_label>Radiprodil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female between 2 and 14 months of age

          -  Onset of spasms has occurred within 3 months of study start

          -  The diagnosis of infantile spasms (IS)

          -  Subject has drug-resistant IS

        Exclusion Criteria:

          -  Subject has hematocrit greater than 60

          -  Subject has any medical condition that, in the opinion of the Investigator, could
             jeopardize or would compromise the subject's ability to participate in this study

          -  Subject has a history or current condition predisposing to respiratory dysfunction

          -  Concomitant treatment with felbamate

          -  Ketogenic diet

          -  Previous treatment for IS other than Standard-of-Care (StoC)

          -  Clinically significant lab abnormalities

          -  Clinically significant abnormality on ECG that, in the opinion of the Investigator,
             increases the safety risks of participating in the study

          -  Subject has a lethal or potentially lethal condition other than IS, with a
             significant risk of death before 18 months of age

          -  Body weight is below 4 kg

          -  Known history of severe anaphylactic reaction secondary to medication intake or
             serious blood dyscrasias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>14 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>+1 887 822 9493</phone>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>July 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiprodil</keyword>
  <keyword>Infantile spasms</keyword>
  <keyword>IS</keyword>
  <keyword>Infantile</keyword>
  <keyword>Spasms</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Paediatrics</keyword>
  <keyword>Drug-resistant</keyword>
  <keyword>West Syndrome</keyword>
  <keyword>Hypsarrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Muscle Cramp</mesh_term>
    <mesh_term>Spasms, Infantile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
